CELMoDs and the Future of Multiple Myeloma Treatment

 


What is Multiple myeloma and How is it to be treated?

Multiple myeloma is a cancer of plasma cells, and it affects approximately 138,000 people worldwide. The multiple myeloma market is dominated by several drugs, with REVLIMID being the leading therapy. However, with the entry of CELMoDs, such as iberdomide, many believe that they could be a worthy successor to REVLIMID.

Generic competition to REVLIMID

REVLIMID, also known as lenalidomide, is one of the most widely prescribed drugs for multiple myeloma. However, the drug has faced significant competition in recent years, with the entry of generic versions in 2022. The introduction of generic REVLIMID has had a considerable impact on the multiple myeloma market, with many patients switching to cheaper alternatives.

The arrival of CELMODS

CELMoDs, or cereblon modulating drugs, are a new class of drugs that work in a similar way to REVLIMID. They are designed to modify the activity of cereblon, a protein that plays a crucial role in the function of the immune system. The first CELMoD to receive FDA approval was iberdomide in February 2022.

Mechanistic differences between CELMODs and IMiDs

IMiDs and CELMoDs share a common target, Cereblon, but CELMoDs are more selective and efficient in degrading proteins. Unlike IMiDs, which are known to have off-target effects, CELMoDs have been designed to bind selectively to Cereblon and target only the proteins involved in cancer cell growth. This selectivity is expected to translate into improved efficacy and safety.

Future of CELMODs

The future of CELMoDs looks promising, with several CELMoDs in the pipeline. Iberdomide, a novel CELMoD, has received FDA approval for clinical trials and has shown promising results in Phase 1 studies. This drug has shown a good safety profile and significant anti-tumor activity in patients with relapsed or refractory multiple myeloma. The drug's mechanism of action has also been found to be more potent than REVLIMID, making it a potential successor to REVLIMID.

Conclusion

The multiple myeloma market has seen significant advancements in the past few years, with new therapies such as CELMoDs emerging as a worthy successor to REVLIMID. These drugs have been designed to overcome the limitations of existing therapies and have shown promising results in preclinical and clinical studies. With the arrival of drugs like Iberdomide, the future of CELMoDs looks promising. However, the long-term efficacy and safety of these drugs need to be established through rigorous clinical trials. Nonetheless, CELMoDs offer hope for patients with multiple myeloma, providing new avenues for the treatment of this challenging disease.

Related Reports

B Cell Chronic Lymphocytic Leukemia Market

DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


B-Cell Lymphomas Market

DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Behcet’s Syndrome Market 

DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom.


Neoantigen-based Personalized Cancer therapeutic Vaccines 

DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Glioblastoma Multiforme Market

DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.


Latest Reports By DelveInsight

Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market


To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting

Recent Blog’s By DelveInsight:

Comments

Post a Comment

Popular posts from this blog

Eli Lilly’s Donanemab: The FDA’s Latest Approval in Alzheimer’s Disease Treatment

Image
  The Birth of a Breakthrough Eli Lilly’s groundbreaking drug, Donanemab, has recently received FDA approval, marking a significant milestone in Alzheimer’s disease treatment . This innovative therapy, designed to target and reduce amyloid plaques in the brain, offers new hope for patients battling this debilitating condition. Donanemab’s approval comes at a pivotal moment, as it represents a major advancement in the Alzheimer’s disease pipeline, promising improved outcomes for those affected. Navigating Regulatory Waters The journey of Donanemab through the regulatory landscape was complex, characterized by rigorous scrutiny and extensive clinical trials. Eli Lilly’s success in obtaining FDA approval highlights the drug’s potential to revolutionize Alzheimer’s disease therapies . This regulatory endorsement not only underscores the efficacy and safety of Donanemab but also sets a new standard for the evaluation of future treatments. Donanemab: Cost and Coverage As with many groundbre
Read more

Bulimia Nervosa Market Insight, Epidemiology And Market Forecast - 2032":

Image
Bulimia Nervosa , a serious eating disorder characterized by binge eating followed by purging behaviors, presents significant challenges in both diagnosis and treatment. As the global understanding of mental health disorders expands, so does the focus on conditions like Bulimia Nervosa, driving advancements in research and therapeutic development. Bulimia Nervosa Market Overview and Size The Bulimia Nervosa market size is poised for growth, driven by increasing awareness and improved diagnostic capabilities worldwide. The market size is expected to expand significantly by 2032, reflecting a rising incidence and prevalence of the disorder across various demographics. Key Bulimia Nervosa Players and Collaborations Leading Bulimia Nervosa companies such as - J ohnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Allergan, Inc., Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb Company, GlaxoSmithKline p
Read more